Drug manufacturer Bausch Health last week said on the U.S. Health Resources and Services Administration website that its branded NDCs “will once again be available at the 340B ceiling price” through AmeriSourceBergen Corp. (ABC) “for eligible 340B purchases made by 340B covered entities and 340B contract pharmacies.”
Bausch Health blindsided 340B covered entities on New Year’s Eve, announcing that starting the very next day, Jan. 1, more than 200 of its branded products and future branded products would no longer be available through ABC “for 340B covered entities and 340B contract pharmacies for purchases at the 340B ceiling price.” No explanation for the disruption was ever given.
340B Report learned early this month that 340B pricing on Bausch Health products was being restored to ABC’s ordering platforms.
Last week, Bausch Health posted on HRSA’s website a form letter to covered entities dated Jan. 29. It says, “We are pleased to announce that, effective immediately, all Bausch Health’s branded prescription NDCs” listed in an attachment “will once again be available at the 340B ceiling price through Amerisource Bergen for eligible 340B purchases made by 340B covered entities and 340B contract pharmacies.” “This change only restores Amerisource Bergen to those national and regional wholesalers through which covered entities may access the 340B ceiling price on these products, and it does not affect the ability of any covered entity or contract pharmacy to make such purchases through our other national or regional distributor partners.”
